Is semaglutide the same as Ozempic and Wegovy?

Yes, it is the same molecule. The brands differ by indication and dose: Ozempic for type 2 diabetes, Wegovy for weight management, Rybelsus as the oral formulation.

Why does semaglutide only need weekly dosing?

The Aib8 substitution blocks DPP-4 cleavage and the C18 diacid chain binds albumin, which together extend the half-life from minutes to about a week.

What does 94% homology mean?

That the sequence is nearly identical to human GLP-1 — the differences are a small number of deliberate substitutions plus the fatty-acid attachment.

GLP-1 & Incretin Science

What Is Semaglutide? Structure, Mechanism and Evidence

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

Semaglutide is a peptide analogue of human GLP-1 sharing roughly 94% sequence homology with the native hormone. Three modifications give it a once-weekly half-life: an Aib substitution at position 8 that blocks DPP-4 cleavage, a C18 diacid chain that binds albumin, and an Arg34Lys substitution. It is marketed as Ozempic, Wegovy and Rybelsus.

Key facts

Class: GLP-1 receptor agonist (peptide analogue)
Developer: Novo Nordisk
Molecular weight: ~4,114 Da
Molecular formula: C187H291N45O59
PubChem CID: 56843331
Homology to native GLP-1: ~94%
Half-life: About one week
Brands: Ozempic, Wegovy, Rybelsus

What was changed from the natural hormone

Native GLP-1 has a half-life of one to two minutes, which makes it useless as a medicine. Semaglutide makes three changes. Alanine at position 8 is replaced with α-aminoisobutyric acid (Aib), which DPP-4 cannot cleave. Lysine 26 carries a C18 diacid chain attached through a γGlu-2xOEG linker, which binds reversibly to serum albumin and shields the peptide from renal clearance. Arginine 34 is substituted for lysine so the fatty acid attaches at a single defined site. The result is a half-life of about a week.

How albumin binding actually extends half-life

This is worth understanding because the same trick appears in liraglutide, retatrutide and most modern incretin analogues. Albumin is a large, abundant, long-lived plasma protein. A peptide bound to it is too large for glomerular filtration and is physically shielded from proteases. Because binding is reversible, a small free fraction remains available to engage the receptor at any moment, and the albumin-bound pool acts as a slow-release depot. Chain length tunes the effect: liraglutide's C16 chain gives roughly a day, semaglutide's C18 diacid gives about a week.

The three products and why they differ

Ozempic is semaglutide for type 2 diabetes, injected weekly. Wegovy is the same molecule at higher dose for weight management. Rybelsus is oral semaglutide, co-formulated with the absorption enhancer SNAC and taken daily with dosing conditions — a fasting window and a defined water volume — because a peptide cannot otherwise survive the stomach.

SELECT and cardiovascular outcomes

The SELECT trial enrolled 17,604 participants aged 45 or over with a BMI of 27 or above, established cardiovascular disease and no diabetes, across 41 countries. Semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% against placebo, published in the New England Journal of Medicine in 2023. This mattered because it moved the class from weight reduction as an endpoint in itself to demonstrated hard-outcome benefit.

Where it sits now

Semaglutide is no longer the most effective incretin available — SURMOUNT-5 showed tirzepatide producing substantially greater reduction head-to-head — but it has by far the largest outcome-trial evidence base, and additional indications including heart failure with preserved ejection fraction and peripheral artery disease have been under regulatory review.

Extended research context

The GLP-1 & Incretin Science deep dive

Deep dive: the two routes to a bigger effect

Every compound trying to beat GLP-1 alone has taken one of two routes. The first adds more receptors from the same hormone family — GIP in tirzepatide, GIP and glucagon in retatrutide. The second adds a non-incretin satiety hormone, which in practice means amylin: CagriSema combines cagrilintide with semaglutide, and amycretin engages both receptors from one molecule. Both routes work, because they recruit signalling pathways that do not fully overlap. Neither has escaped the constraint that binds all of them, which is that gastrointestinal tolerability worsens as effect size grows.

Deep dive: why a percentage is not a result

The most-quoted numbers in this field are the least comparable. REDEFINE 1 reported 22.7% and 20.4% for the same compound in the same trial — the first among participants who adhered to treatment, the second across everyone randomised. TRIUMPH-1 reported 28.3% in an uncomplicated obesity population while TRIUMPH-3 reported up to 22.6% in adults with established cardiovascular disease, using the same compound. Before any two figures can be compared they have to match on estimand, population, duration, comparator and whether the number is placebo-adjusted. Most published comparisons match on none of them.

Deep dive: what happens after the trial stops

Every headline figure describes weight while treatment continues. The STEP-1 extension found that a year after semaglutide was stopped, participants had given back roughly two-thirds of what they lost, moving from 17.3% mean reduction to a net 5.6% — though average weight remained below baseline and nearly half stayed at least 5% down. Meta-analysis puts regain at around 0.8 kg per month. This is why maintenance studies such as TRIUMPH-6 matter more to the field's future than another two points of peak reduction.

Research applications

▸Comparing incretin and amylin compounds on a like-for-like basis
▸Interpreting estimands, thresholds and placebo-adjusted figures in trial reports
▸Tracking the obesity pipeline across sponsors and jurisdictions
▸Understanding receptor pharmacology behind GLP-1, GIP, glucagon and amylin
▸Distinguishing licensed medicines from investigational compounds

Handling checklist

✓Identify which estimand a quoted percentage comes from before citing it
✓Check the trial population and baseline BMI against the comparison you are making
✓Confirm the duration and whether the reduction curve had plateaued
✓Read discontinuation rates alongside efficacy figures
✓Verify every NCT identifier against ClinicalTrials.gov rather than secondary reporting

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Comparing headline percentages across different trials

Fix: Population, duration, estimand and comparator all differ; the numbers are not interchangeable.

✗ Quoting the larger of two figures from the same trial

Fix: Name the estimand. Efficacy and treatment-policy answer different questions.

✗ Treating peak reduction as a durable outcome

Fix: Substantial regain follows cessation across the class; peak figures describe a maintained state.

✗ Assuming an oral route means a weaker mechanism

Fix: Route and receptor count are independent. Orforglipron is weaker because it hits one receptor, not because it is a tablet.

✗ Reading investigational compounds as available treatments

Fix: Most of this pipeline holds no authorisation anywhere; mazdutide is approved only in China.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Is semaglutide the same as Ozempic and Wegovy?: Yes, it is the same molecule. The brands differ by indication and dose: Ozempic for type 2 diabetes, Wegovy for weight management, Rybelsus as the oral formulation.
Why does semaglutide only need weekly dosing?: The Aib8 substitution blocks DPP-4 cleavage and the C18 diacid chain binds albumin, which together extend the half-life from minutes to about a week.
What does 94% homology mean?: That the sequence is nearly identical to human GLP-1 — the differences are a small number of deliberate substitutions plus the fatty-acid attachment.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More GLP-1 & Incretin Science articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum